Occurrence of Dementia According to Baseline Timed Up and Go Test Results (n = 49,283)
| . | Person-years . | Number of Occurrence . | Rate (1/1,000) . | HR (95% CI) . | aHR (95% CI)a . | aSHR (95% CI)b . |
|---|---|---|---|---|---|---|
| All dementiac | 188,963.5 | 950 | 5.0 | |||
| Normal TUG | 160,451.6 | 752 | 4.7 | 1.00 | 1.00 | 1.00 |
| Impaired TUG | 28,511.9 | 198 | 6.9 | 1.40 (1.20–1.64) | 1.34 (1.14–1.57) | 1.33 (1.14–1.56) |
| Alzheimer’s diseased | 189,247.9 | 777 | 4.1 | |||
| Normal TUG | 160,667.9 | 622 | 3.9 | 1.00 | 1.00 | 1.00 |
| Impaired TUG | 28,580.0 | 155 | 5.4 | 1.32 (1.11–1.58) | 1.26 (1.06–1.51) | 1.25 (1.05–1.49) |
| Vascular dementiae | 190,185.8 | 193 | 1.0 | |||
| Normal TUG | 161,404.6 | 146 | 0.9 | 1.00 | 1.00 | 1.00 |
| Impaired TUG | 28,781.2 | 47 | 1.6 | 1.72 (1.23–2.38) | 1.65 (1.19–2.30) | 1.64 (1.18–2.28) |
| . | Person-years . | Number of Occurrence . | Rate (1/1,000) . | HR (95% CI) . | aHR (95% CI)a . | aSHR (95% CI)b . |
|---|---|---|---|---|---|---|
| All dementiac | 188,963.5 | 950 | 5.0 | |||
| Normal TUG | 160,451.6 | 752 | 4.7 | 1.00 | 1.00 | 1.00 |
| Impaired TUG | 28,511.9 | 198 | 6.9 | 1.40 (1.20–1.64) | 1.34 (1.14–1.57) | 1.33 (1.14–1.56) |
| Alzheimer’s diseased | 189,247.9 | 777 | 4.1 | |||
| Normal TUG | 160,667.9 | 622 | 3.9 | 1.00 | 1.00 | 1.00 |
| Impaired TUG | 28,580.0 | 155 | 5.4 | 1.32 (1.11–1.58) | 1.26 (1.06–1.51) | 1.25 (1.05–1.49) |
| Vascular dementiae | 190,185.8 | 193 | 1.0 | |||
| Normal TUG | 161,404.6 | 146 | 0.9 | 1.00 | 1.00 | 1.00 |
| Impaired TUG | 28,781.2 | 47 | 1.6 | 1.72 (1.23–2.38) | 1.65 (1.19–2.30) | 1.64 (1.18–2.28) |
Note: aHR = Adjusted hazard ratio; aSHR = Adjusted subdistribution hazard ratio; HR = Hazard ratio, All the subjects were 66 years old at screening.
Multivariate model included sex, smoking status, and past medical history (stroke, hypertension, diabetes mellitus, hypercholesterolemia), depressive symptom, and baseline cognitive function.
Competing risk analysis regarding death as competitive risk of dementia occurrence. Multivariate model included sex, smoking status, and past medical history (stroke, hypertension, diabetes mellitus, hypercholesterolemia), depression, and baseline cognitive function.
Dementia was defined as starting acetylcholinesterase inhibitors or N-Methyl-D-Aspartate receptor antagonist (donepezil, rivastigmine, galantamine, or memantine) with a diagnosis code of dementia (F00, F01, F02, F03, G30, F051, or G311) by the International Classification of Diseases 10th Revision (ICD-10) after the health screening day.
Alzheimer’s disease was defined as starting acetylcholinesterase inhibitors or N-Methyl-D-Aspartate receptor antagonist (donepezil, rivastigmine, galantamine, or memantine) with an ICD-10 diagnosis code of Alzheimer’s disease (F00 or G30) after the health screening day.
Vascular dementia was defined as starting acetylcholinesterase inhibitors or N-Methyl-D-Aspartate receptor antagonist (donepezil, rivastigmine, galantamine, or memantine) with an ICD-10 diagnosis code of vascular dementia (F01) after the health screening day.
Occurrence of Dementia According to Baseline Timed Up and Go Test Results (n = 49,283)
| . | Person-years . | Number of Occurrence . | Rate (1/1,000) . | HR (95% CI) . | aHR (95% CI)a . | aSHR (95% CI)b . |
|---|---|---|---|---|---|---|
| All dementiac | 188,963.5 | 950 | 5.0 | |||
| Normal TUG | 160,451.6 | 752 | 4.7 | 1.00 | 1.00 | 1.00 |
| Impaired TUG | 28,511.9 | 198 | 6.9 | 1.40 (1.20–1.64) | 1.34 (1.14–1.57) | 1.33 (1.14–1.56) |
| Alzheimer’s diseased | 189,247.9 | 777 | 4.1 | |||
| Normal TUG | 160,667.9 | 622 | 3.9 | 1.00 | 1.00 | 1.00 |
| Impaired TUG | 28,580.0 | 155 | 5.4 | 1.32 (1.11–1.58) | 1.26 (1.06–1.51) | 1.25 (1.05–1.49) |
| Vascular dementiae | 190,185.8 | 193 | 1.0 | |||
| Normal TUG | 161,404.6 | 146 | 0.9 | 1.00 | 1.00 | 1.00 |
| Impaired TUG | 28,781.2 | 47 | 1.6 | 1.72 (1.23–2.38) | 1.65 (1.19–2.30) | 1.64 (1.18–2.28) |
| . | Person-years . | Number of Occurrence . | Rate (1/1,000) . | HR (95% CI) . | aHR (95% CI)a . | aSHR (95% CI)b . |
|---|---|---|---|---|---|---|
| All dementiac | 188,963.5 | 950 | 5.0 | |||
| Normal TUG | 160,451.6 | 752 | 4.7 | 1.00 | 1.00 | 1.00 |
| Impaired TUG | 28,511.9 | 198 | 6.9 | 1.40 (1.20–1.64) | 1.34 (1.14–1.57) | 1.33 (1.14–1.56) |
| Alzheimer’s diseased | 189,247.9 | 777 | 4.1 | |||
| Normal TUG | 160,667.9 | 622 | 3.9 | 1.00 | 1.00 | 1.00 |
| Impaired TUG | 28,580.0 | 155 | 5.4 | 1.32 (1.11–1.58) | 1.26 (1.06–1.51) | 1.25 (1.05–1.49) |
| Vascular dementiae | 190,185.8 | 193 | 1.0 | |||
| Normal TUG | 161,404.6 | 146 | 0.9 | 1.00 | 1.00 | 1.00 |
| Impaired TUG | 28,781.2 | 47 | 1.6 | 1.72 (1.23–2.38) | 1.65 (1.19–2.30) | 1.64 (1.18–2.28) |
Note: aHR = Adjusted hazard ratio; aSHR = Adjusted subdistribution hazard ratio; HR = Hazard ratio, All the subjects were 66 years old at screening.
Multivariate model included sex, smoking status, and past medical history (stroke, hypertension, diabetes mellitus, hypercholesterolemia), depressive symptom, and baseline cognitive function.
Competing risk analysis regarding death as competitive risk of dementia occurrence. Multivariate model included sex, smoking status, and past medical history (stroke, hypertension, diabetes mellitus, hypercholesterolemia), depression, and baseline cognitive function.
Dementia was defined as starting acetylcholinesterase inhibitors or N-Methyl-D-Aspartate receptor antagonist (donepezil, rivastigmine, galantamine, or memantine) with a diagnosis code of dementia (F00, F01, F02, F03, G30, F051, or G311) by the International Classification of Diseases 10th Revision (ICD-10) after the health screening day.
Alzheimer’s disease was defined as starting acetylcholinesterase inhibitors or N-Methyl-D-Aspartate receptor antagonist (donepezil, rivastigmine, galantamine, or memantine) with an ICD-10 diagnosis code of Alzheimer’s disease (F00 or G30) after the health screening day.
Vascular dementia was defined as starting acetylcholinesterase inhibitors or N-Methyl-D-Aspartate receptor antagonist (donepezil, rivastigmine, galantamine, or memantine) with an ICD-10 diagnosis code of vascular dementia (F01) after the health screening day.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
